Deep space is most likely going to be humanity's final frontier, and space travel will undoubtedly become much more common in the future. However, space is a very hostile environment not only because of the technical difficulties that entail going there, but also because of the detrimental effects that constant microgravity has on the human body. Some examples of these are bone loss, muscle atrophy, and liver and kidney problems, as well as space motion sickness.

It should come as no surprise that astronauts resort to various drugs to ameliorate the symptoms caused by microgravity. Unfortunately for them, microgravity has been noted to have a significant impact on the pharmacokinetics of certain drugs, which could lead to altered efficacy and unexpected outcomes. In particular, delivering an accurate amount of a drug to the brain has become a key problem in space health.

In a recent effort to shed some light onto this issue, a team of scientists from Beijing Institute of Technology, China, studied the effects that microgravity has on P-glycoprotein (P-gp), an important efflux transporter. Their results are detailed in their paper published in Space: Science and Technology, on 17 Jun 2021.

On Sept. 15, 2021, the next batch of space tourists are set to lift off aboard a SpaceX rocket. Organized and funded by entrepreneur Jared Isaacman, the Inspiration4 mission touts itself as "the first all-civilian mission to orbit" and represents a new type of space tourism.

The four crew members will not be the first space tourists this year. In the past few months, the world witnessed billionaires Richard Branson and Jeff Bezos launching themselves and a lucky few others into space on brief suborbital trips.